% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Zhang:309639,
      author       = {X.-W. Zhang$^*$ and D. Jäger$^*$ and S. Zschäbitz$^*$},
      title        = {{M}anagement of {A}dvanced {R}enal {C}ell {C}arcinoma.},
      journal      = {Oncology research and treatment},
      volume       = {49},
      number       = {1-2},
      issn         = {2296-5270},
      address      = {Basel},
      publisher    = {Karger},
      reportid     = {DKFZ-2026-00273},
      pages        = {26 - 34},
      year         = {2026},
      note         = {#NCTZFB9#},
      abstract     = {Management of advanced renal cell carcinoma (RCC) has
                      evolved significantly in the last years. Systemic treatment
                      of clear cell RCC, the predominant subtype, is performed
                      with immune checkpoint inhibitors (ICIs), anti-VEGF tyrosine
                      kinase inhibitor (TKI), HIF2α inhibitors and mTOR
                      inhibitors.The application of ICI in early disease has
                      raised new challenges regarding subsequent therapy
                      strategies and management of new toxicities of
                      immunotherapy-based combination therapies. Systemic
                      treatment for non-clear cell RCC is challenging due to the
                      lack of robust clinical evidence for effective treatment
                      regimens. Recent phase-2 data also indicate a benefit of
                      ICI-combination therapies for non-clear cell RCC. For
                      oligometastatic or oligoprogressive diseases, local therapy
                      with cytoreductive nephrectomy, metastasectomy or
                      stereotactic radiation can be considered. This review
                      provides a comprehensive overview of current treatment
                      strategies for advanced RCC, including systemic therapies
                      for both clear cell and non-clear cell subtypes, management
                      of treatment-associated toxicities, and the role of local
                      therapies.Combination therapy for clear cell RCC is standard
                      in first-line therapy and published data also support its
                      use in non-clear cell carcinoma. Local therapies can be
                      considered in selected patients. In subsequent treatment
                      lines TKIs, mTOR inhibitors and the HIF2α inhibitor
                      belzutifan are used.},
      subtyp        = {Review Article},
      keywords     = {Humans / Carcinoma, Renal Cell: therapy / Carcinoma, Renal
                      Cell: pathology / Carcinoma, Renal Cell: mortality / Kidney
                      Neoplasms: therapy / Kidney Neoplasms: pathology / Kidney
                      Neoplasms: mortality / Combined Modality Therapy: methods /
                      Immune Checkpoint Inhibitors: therapeutic use / Nephrectomy
                      / Protein Kinase Inhibitors: therapeutic use / Molecular
                      Targeted Therapy: methods / Antineoplastic Combined
                      Chemotherapy Protocols: therapeutic use / Neoplasm Staging /
                      Checkpoint inhibitor (Other) / HIF2α inhibitor (Other) /
                      Metastasectomy (Other) / Renal cell carcinoma (Other) /
                      Tyrosine kinase inhibitor (Other) / Immune Checkpoint
                      Inhibitors (NLM Chemicals) / Protein Kinase Inhibitors (NLM
                      Chemicals)},
      cin          = {HD02},
      ddc          = {350},
      cid          = {I:(DE-He78)HD02-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40494322},
      doi          = {10.1159/000546879},
      url          = {https://inrepo02.dkfz.de/record/309639},
}